ALUNBRIG® (brigatinib) Expert Opinion Video Series: Real-world data of subsequent systemic anticancer treatments following first-line ALUNBRIG in patients with ALK+ aNSCLC from the ALTA-1L trial
Prescribing information is available at the top of the page.
Listen to Dr Sharmistha Ghosh provide an overview of the results from the ALTA-1L retrospective chart review study which provides insight into the use of subsequent systemic anticancer treatments in patients with ALK+ aNSCLC following discontinuation of 1L ALUNBRIG from the ALTA-1L trial.
Dr Ghosh discusses specific data relating to lorlatinib, as the most commonly used 2L ALK TKI used within the retrospective chart review, and as a licensed treatment option after progression on 1L ALUNBRIG in Great Britain.
2L, second-line; 1L, first-line; ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; aNSCLC, advanced non-small cell lung cancer; TKI, tyrosine kinase inhibitor.
To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.
